G

Galapagos NV
D

GLPG

27.340
USD
0.58
(2.18%)
مغلق
حجم التداول
0
الربح لكل سهم
-3
العائد الربحي
-
P/E
-9
حجم السوق
1,801,625,921
أصول ذات صلة
ABBV
ABBV
5.160
(2.67%)
198.440 USD
ALNY
ALNY
3.98
(1.56%)
259.33 USD
AMGN
AMGN
-2.15
(-0.76%)
281.20 USD
A
ARRY
-0.13000
(-2.53%)
5.01000 USD
C
CRSP
0.480
(1.27%)
38.180 USD
G
GLYC
0.00110
(0.42%)
0.26400 USD
INCY
INCY
0.500
(0.81%)
62.500 USD
REGN
REGN
15.98
(2.71%)
606.12 USD
S
SGMO
-0.01210
(-1.63%)
0.72800 USD
VRTX
VRTX
2.22
(0.45%)
500.92 USD
المزيد
الأخبار المقالات

العنوان: Galapagos NV

القطاع: Healthcare
الصناعة: Biotechnology
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, aBCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.